Interaction of NcRNAs and the PI3K/AKT/mTOR Pathway: Implications for Osteosarcoma

Overview

Journal Open Life Sci

Specialty Biology

Date 2024 Aug 9

PMID 39119480

Authors

Weilin Shao

Yan Feng

Jin Huang

Tingyu Li

Shengguai Gao

Yihao Yang

Dongqi Li

Zuozhang Yang

Zhihong Yao

Affiliations

Soon will be listed here.

Abstract

Osteosarcoma (OS) is the most common primary malignant bone tumor in children and adolescents, and is characterized by high heterogeneity, high malignancy, easy metastasis, and poor prognosis. Recurrence, metastasis, and multidrug resistance are the main problems that limit the therapeutic effect and prognosis of OS. PI3K/AKT/mTOR signaling pathway is often abnormally activated in OS tissues and cells, which promotes the rapid development, metastasis, and drug sensitivity of OS. Emerging evidence has revealed new insights into tumorigenesis through the interaction between the PI3K/AKT/mTOR pathway and non-coding RNAs (ncRNAs). Therefore, we reviewed the interactions between the PI3K/AKT/mTOR pathway and ncRNAs and their implication in OS. These interactions have the potential to serve as cancer biomarkers and therapeutic targets in clinical applications.

References

Zhang C, Na N, Liu L, Qiu Y . CircRNA hsa_circ_0005909 Promotes Cell Proliferation of Osteosarcoma Cells by Targeting miR-338-3p/HMGA1 Axis. Cancer Manag Res. 2021; 13:795-803. PMC: 7850455. DOI: 10.2147/CMAR.S285118. View

Ning B, Liu Y, Huang T, Wei Y . Autophagy and its role in osteosarcoma. Cancer Med. 2023; 12(5):5676-5687. PMC: 10028045. DOI: 10.1002/cam4.5407. View

Ma H, Su R, Feng H, Guo Y, Su G . Long noncoding RNA UCA1 promotes osteosarcoma metastasis through CREB1-mediated epithelial-mesenchymal transition and activating PI3K/AKT/mTOR pathway. J Bone Oncol. 2019; 16:100228. PMC: 6463206. DOI: 10.1016/j.jbo.2019.100228. View

Kara G, Calin G, Ozpolat B . RNAi-based therapeutics and tumor targeted delivery in cancer. Adv Drug Deliv Rev. 2022; 182:114113. DOI: 10.1016/j.addr.2022.114113. View

Li P, Huang D, Gu X . Exploring the dual role of circRNA and PI3K/AKT pathway in tumors of the digestive system. Biomed Pharmacother. 2023; 168:115694. DOI: 10.1016/j.biopha.2023.115694. View

Mirzaei S, Gholami M, Hushmandi K, Hashemi F, Zabolian A, Canadas I . The long and short non-coding RNAs modulating EZH2 signaling in cancer. J Hematol Oncol. 2022; 15(1):18. PMC: 8892735. DOI: 10.1186/s13045-022-01235-1. View

Jin B, Jin D, Zhuo Z, Zhang B, Chen K . MiR-1224-5p Activates Autophagy, Cell Invasion and Inhibits Epithelial-to-Mesenchymal Transition in Osteosarcoma Cells by Directly Targeting PLK1 Through PI3K/AKT/mTOR Signaling Pathway. Onco Targets Ther. 2020; 13:11807-11818. PMC: 7680192. DOI: 10.2147/OTT.S274451. View

Li C, Zhang S, Qiu T, Wang Y, Ricketts D, Qi C . Upregulation of long non-coding RNA NNT-AS1 promotes osteosarcoma progression by inhibiting the tumor suppressive miR-320a. Cancer Biol Ther. 2018; 20(4):413-422. PMC: 6422455. DOI: 10.1080/15384047.2018.1538612. View

Fan H, Wang S, Shi Y, Sun J . MicroRNA-340-5p inhibits the malignant phenotypes of osteosarcoma by directly targeting NRF2 and deactivating the PI3K/AKT pathway. Eur Rev Med Pharmacol Sci. 2021; 25(10):3661-3669. DOI: 10.26355/eurrev_202105_25932. View

10.

Liu Z, Wang J, Lv R . Downregulation of long non-coding RNA DBH-AS1 inhibits osteosarcoma progression by PI3K-AKT signaling pathways and indicates good prognosis. Eur Rev Med Pharmacol Sci. 2019; 23(4):1418-1427. DOI: 10.26355/eurrev_201902_17098. View

11.

Chen D, Lei C, Liu W, Shao M, Sun M, Guo J . Reduction-responsive nucleic acid nanocarrier-mediated miR-22 inhibition of PI3K/AKT pathway for the treatment of patient-derived tumor xenograft osteosarcoma. Bioact Mater. 2023; 28:376-385. PMC: 10382964. DOI: 10.1016/j.bioactmat.2023.05.012. View

12.

Li X, Sun X, Xu H, Pan H, Liu Y, He L . Circ_ORC2 enhances the regulatory effect of miR-19a on its target gene PTEN to affect osteosarcoma cell growth. Biochem Biophys Res Commun. 2019; 514(4):1172-1178. DOI: 10.1016/j.bbrc.2019.04.188. View

13.

Gao L, Jia S, Zhang Q, Xia Y, Li C, Li Y . MicroRNA-802 promotes the progression of osteosarcoma through targeting p27 and activating PI3K/AKT pathway. Clin Transl Oncol. 2021; 24(2):266-275. DOI: 10.1007/s12094-021-02683-w. View

14.

Miwa S, Shirai T, Yamamoto N, Hayashi K, Takeuchi A, Igarashi K . Current and Emerging Targets in Immunotherapy for Osteosarcoma. J Oncol. 2019; 2019:7035045. PMC: 6332920. DOI: 10.1155/2019/7035045. View

15.

Zhang L, Zhao G, Ji S, Yuan Q, Zhou H . Downregulated Long Non-Coding RNA MSC-AS1 Inhibits Osteosarcoma Progression and Increases Sensitivity to Cisplatin by Binding to MicroRNA-142. Med Sci Monit. 2020; 26:e921594. PMC: 7081928. DOI: 10.12659/MSM.921594. View

16.

Han W, Liu J . LncRNA-p21 inhibited the proliferation of osteosarcoma cells via the miR-130b/PTEN/AKT signaling pathway. Biomed Pharmacother. 2017; 97:911-918. DOI: 10.1016/j.biopha.2017.11.014. View

17.

Jiang N, Wang X, Xie X, Liao Y, Liu N, Liu J . lncRNA DANCR promotes tumor progression and cancer stemness features in osteosarcoma by upregulating AXL via miR-33a-5p inhibition. Cancer Lett. 2017; 405:46-55. DOI: 10.1016/j.canlet.2017.06.009. View

18.

Zoi V, Kyritsis A, Galani V, Lazari D, Sioka C, Voulgaris S . The Role of Curcumin in Cancer: A Focus on the PI3K/Akt Pathway. Cancers (Basel). 2024; 16(8). PMC: 11048628. DOI: 10.3390/cancers16081554. View

19.

Liu Y, Qiu G, Luo Y, Li S, Xu Y, Zhang Y . Circular RNA ROCK1, a novel circRNA, suppresses osteosarcoma proliferation and migration via altering the miR-532-5p/PTEN axis. Exp Mol Med. 2022; 54(7):1024-1037. PMC: 9356001. DOI: 10.1038/s12276-022-00806-z. View

20.

Wang Q, Liu M, Bu J, Deng J, Jiang B, Jiang L . miR-485-3p regulated by MALAT1 inhibits osteosarcoma glycolysis and metastasis by directly suppressing c-MET and AKT3/mTOR signalling. Life Sci. 2020; 268:118925. DOI: 10.1016/j.lfs.2020.118925. View